Cathie Wood Bets Big On This Peter Thiel-Backed Coinbase Rival As Bitcoin Crashes Below $91,000 - Grayscale Bitcoin Mini Trust ( BTC ) Common units of fractional undivided beneficial interest ( ARCA:BTC )
On Monday, Cathie Wood-led Ark Invest executed significant trades involving Bullish ( NYSE:BLSH ) , Reddit Inc. ( NYSE:RDDT ) , and Pinterest Inc. ( NYSE:PINS ) .
Can NTLA Stock Bounce Back in 2026 After Recent Pipeline Setbacks?
Intellia faces FDA clinical holds on key ATTR studies as it readies crucial HAE data in 2026, making lonvo-z pivotal for its near-term outlook.
Cathie Dumps AMD And Reddit Shares Amid Tech Bloodbath, Ark Doubles Down On Tom Lee And Peter Thiel Crypto Plays - Advanced Micro Devices ( NASDAQ:AMD )
On Thursday, Cathie Wood-led Ark Invest executed significant trades, notably involving Circle Internet Group Inc ( NYSE:CRCL ) , Bitmine Immersion Technologies Inc ( NYSE:BMNR ) , Bullish ( NYSE:BLSH ) , Advanced Micro Devices Inc ( NASDAQ:AMD ) , and Reddit Inc ( NYSE:RDDT ) .
Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference - Beam Therapeutics ( NASDAQ:BEAM )
CAMBRIDGE, Mass., Nov. 12, 2025 ( GLOBE NEWSWIRE ) -- Beam Therapeutics Inc. ( NASDAQ:BEAM ) , a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in a fireside chat during the 2025 Jefferies London Healthcare ...
Cathie Wood Dumps $2.4 Million Worth Of Tesla Stock, Doubles Down On These AI Stocks - Tesla ( NASDAQ:TSLA )
On Monday, Cathie Wood-led Ark Invest executed significant trades involving Tesla Inc. ( NASDAQ:TSLA ) , Pony AI Inc. ( NASDAQ:PONY ) , Taiwan Semiconductor Manufacturing Co. Ltd. ( NYSE:TSM ) , and Baidu Inc. ( NASDAQ:BIDU ) . These trades highlight Ark's strategic positioning in the tech and AI ...
Cathie Wood Dumps $2.4 Million Worth Of Tesla Shares, Doubles Down On These AI Stocks - Tesla ( NASDAQ:TSLA )
On Monday, Cathie Wood-led Ark Invest executed significant trades involving Tesla Inc. ( NASDAQ:TSLA ) , Pony AI Inc. ( NASDAQ:PONY ) , Taiwan Semiconductor Manufacturing Co. Ltd. ( NYSE:TSM ) , and Baidu Inc. ( NASDAQ:BIDU ) . These trades highlight Ark's strategic positioning in the tech and AI ...
Ultragenyx Q3 Earnings and Sales Miss Estimates, Increase Y/Y
RARE's Q3 loss widens and revenues miss estimates, despite year-over-year sales growth of key rare disease drugs.
Madrigal Q3 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Up
MDGL's wider Q3 loss fails to deter investors, as soaring Rezdiffra sales drive revenues past estimates and lift the stock.
Novo Nordisk Q3 Earnings & Revenues Miss, GLP-1 Drugs Face US Hurdles
NVO's Q3 profit and revenues miss expectations as Wegovy and Ozempic growth slows amid U.S. compounding and pricing headwinds.
Cathie Wood Goes All-In On Peter Thiel's Crypto Play Bullish With Back-To-Back Million-Dollar Buys - Bullish ( NYSE:BLSH )
On Tuesday, Cathie Wood-led Ark Invest made several significant trades, with the most notable being the purchase of shares in Bullish ( NYSE:BLSH ) . Ark Invest's primary trade of the day was in Bullish, a cryptocurrency exchange backed by billionaire investor and entrepreneur Peter Thiel.
ZTS Q3 Earnings Beat, Revenues Miss, '25 Sales View Cut, Stock Down
Zoetis tops Q3 earnings forecasts but misses on revenues and trims 2025 sales outlook, sending shares lower on weak U.S. results.
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus
XENE reports narrower-than-expected Q3 loss as the biotech advances multiple late-stage studies of azetukalner across epilepsy and mood disorders.
Beam Therapeutics Inc. ( BEAM ) Reports Q3 Loss, Lags Revenue Estimates
Beam Therapeutics (BEAM) delivered earnings and revenue surprises of -12.24% and -25.31%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Cathie Wood Dumps $7.9 Million Worth Of Palantir Stock Despite 121% Revenue Surge - Ark Doubles Down On Peter Thiel's Buzzy Crypto Upstart - Palantir Technologies ( NASDAQ:PLTR )
On Monday, Cathie Wood-led Ark Invest made notable trades, including a significant purchase of Bullish ( NYSE:BLSH ) shares and a sell-off of Palantir Technologies Inc ( NASDAQ:PLTR ) stock.
Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings?
CRISPR Therapeutics is likely to witness an earnings beat as Casgevy sales climb and new CAR-T and in-vivo programs advance.
AGIO's Q3 Loss Narrower Than Expected, Pyrukynd Drives Y/Y Revenues
Agios posts a narrower-than-expected third-quarter loss as Pyrukynd drives a 44% revenue rise, with potential label expansions on the horizon.
Apellis Stock Down Despite Q3 Earnings and Revenues Beat Estimates
APLS shares plunge 31% despite topping Q3 earnings and revenue estimates, as gains were driven by a one-time Sobi payment.
AGIO's Q3 Loss Narrower Than Expected, Pyrukynd Drives Y/Y Revenues
Agios posts a narrower-than-expected third-quarter loss as Pyrukynd drives a 44% revenue rise, with potential label expansions on the horizon.
ALNY Q3 Earnings and Revenues Top Estimates on Higher Amvuttra Sales
Alnylam's Q3 earnings and revenues surge past forecasts, powered by booming Amvuttra sales and a key milestone payment from Roche.
Amarin's Q3 Earnings Lag Estimates, Revenues Beat, Stock Down
AMRN's third-quarter earnings fall short of expectations, but stronger U.S. Vascepa sales push revenues above estimates.
United Therapeutics Q3 Earnings Beat Estimates, Revenues Miss Mark
UTHR beats Q3 earnings forecasts on solid Tyvaso and Orenitram growth, while revenues fall shy of estimates.
RGEN'S Q3 Earnings Beat Estimates, Revenues Surge Y/Y, Stock Down
Repligen posts strong Q3 results with revenue growth and an earnings beat, yet shares dip as tighter EPS guidance tempers investor optimism.
Beam Therapeutics ( BEAM ) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Beam Therapeutics (BEAM) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Beam Therapeutics Inc. ( BEAM ) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Beam Therapeutics (BEAM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
WW International, Replimune Group, Datavault AI, GRAIL And Other Big Stocks Moving Higher On Monday - American Battery Tech ( NASDAQ:ABAT ) , Amazon.com ( NASDAQ:AMZN )
U.S. stocks were higher, with the Nasdaq Composite gaining more than 1% on Monday. Shares of WW International, Inc. ( NASDAQ:WW ) rose sharply during Monday's session after announcing a partnership with Amazon.com, Inc.'s ( NASDAQ:AMZN ) Amazon Pharmacy to make weight management medications ...
Beam Therapeutics Inc. ( BEAM ) 's Technical Outlook is Bright After Key Golden Cross
Is it a good or bad thing when a stock experiences a golden cross technical event?
Can NTLA's In Vivo Pipeline Aid Long-Term Growth Amid Competition?
Intellia banks on its late-stage gene-editing therapies, lonvo-z and nex-z, that could define its long-term growth phase in the gene editing space.
Wall Street Analysts Think Beam Therapeutics ( BEAM ) Could Surge 76.15%: Read This Before Placing a Bet
The mean of analysts' price targets for Beam Therapeutics (BEAM) points to a 76.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Is Beam Therapeutics ( BEAM ) Stock Outpacing Its Medical Peers This Year?
Here is how Beam Therapeutics Inc. (BEAM) and Humana (HUM) have performed compared to their sector so far this year.
Jim Cramer Sees More Upside For Shopify, Likes CoreWeave's AI Moves - Beam Therapeutics ( NASDAQ:BEAM ) , Affirm Holdings ( NASDAQ:AFRM )
On CNBC's "Mad Money Lightning Round," on Tuesday, Jim Cramer recommended buying Affirm Holdings, Inc. ( NASDAQ:AFRM ) . Supporting his view, Rothschild & Co analyst Harry Bartlett, on Oct. 6, upgraded Affirm from Neutral to Buy and raised the price target from $74 to $101.
Is Beam Therapeutics Gaining or Losing Market Support? - Beam Therapeutics ( NASDAQ:BEAM )
Beam Therapeutics's BEAM short interest as a percent of float has fallen 6.25% since its last report. According to exchange reported data, there are now 25.48 million shares sold short, which is 28.49% of all regular shares that are available for trading.
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2025
GeneDx, Twist Bioscience and Wave Life Sciences are emerging as key players in the fast-growing genomics and synthetic biology space.
Cathie Wood Loads Up On Bullish Inc, Pony AI And Robinhood - Dumps Kratos Defense Amid Taiwan Drone Buzz - ARK Autonomous Technology & Robotics ETF ( BATS:ARKQ ) , ARK Innovation ETF ( BATS:ARKK )
On Wednesday, Cathie Wood-led Ark Invest executed significant trades involving Bullish BLSH, Kratos Defense and Security Solutions Inc. KTOS, Pony AI Inc. PONY, and Robinhood Markets Inc. HOOD.
Cathie Wood's Reshuffle Tuesday: Loads Up On AMD, Figma And Bullish, Trims Tempus AI - Grayscale Bitcoin Mini Trust ( BTC ) Common units of fractional undivided beneficial interest ( ARCA:BTC )
On Tuesday, Cathie Wood-led Ark Invest executed significant trades, including buying shares of Advanced Micro Devices Inc. AMD and Bullish Inc. BLSH, while selling shares of Tempus AI Inc. TEM. Additionally, Ark purchased Figma Inc. FIG stock, reflecting strategic adjustments in its investment ...
Why Is Allogene Therapeutics ( ALLO ) Up 9.4% Since Last Earnings Report?
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
1 Reason Every Investor Should Know About CRISPR Therapeutics ( CRSP )
This little company's scientific breakthrough opened up a whole new sliver of the drug market (although it's still leading the developmental race).
Can CRSP's In Vivo Pipeline Aid Long-Term Growth Beyond Casgevy?
CRISPR Therapeutics pushes beyond Casgevy with in vivo programs like CTX310, CTX320 and plans for two more studies by 2025-end.
CRSP vs. BEAM: Which Gene Editing Stock Holds More Potential Right Now?
CRISPR Therapeutics gains momentum with Casgevy sales and a broader pipeline, while Beam Therapeutics advances base-editing therapies still in early stages.
What Does the Market Think About Beam Therapeutics? - Beam Therapeutics ( NASDAQ:BEAM )
Beam Therapeutics's BEAM short percent of float has risen 4.04% since its last report. The company recently reported that it has 24.62 million shares sold short, which is 27.53% of all regular shares that are available for trading.
Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences - Beam Therapeutics ( NASDAQ:BEAM )
CAMBRIDGE, Mass., Aug. 25, 2025 ( GLOBE NEWSWIRE ) -- Beam Therapeutics Inc. BEAM, a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in fireside chats at the following upcoming investor conferences:
CRISPR Therapeutics Gains 41.4% in 3 Months: How to Play the Stock
CRSP surges 41.4% in three months, fueled by promising CTX310 study data and accelerating Casgevy sales.
Cathie Wood's $21 Million Tuesday Move: Peter Thiel's Crypto Play Gets Boost In Ark Portfolio - Grayscale Bitcoin Mini Trust ( BTC ) Common units of fractional undivided beneficial interest ( ARCA:BTC )
Cathie Wood-led Ark Invest made significant trades on Tuesday with notable activity in Bullish BLSH, Robinhood Markets Inc. HOOD, and Tempus AI Inc. TEM. ArrivedBuy shares of homes and vacation rentals for as little as $100. Get Started
Cathie Wood's 'Apocalypse Squad' Play? Ark Scoops Up $14.2 Million Worth Of Robinhood Stock - ARK Autonomous Technology & Robotics ETF ( BATS:ARKQ ) , ARK Innovation ETF ( BATS:ARKK )
Ark Invest, led by Cathie Wood, executed notable trades on Monday, focusing on Robinhood Markets Inc. HOOD and Deere & Co. DE. ArrivedBuy shares of homes and vacation rentals for as little as $100. Get Started Interactive BrokersTrade global markets with low costs and pro-level tools at ...
Pfizer's Investigational Drug Flunks Late-Stage For Sickle Cell Disease - Pfizer ( NYSE:PFE )
Inclacumab fails to reduce VOC rates in sickle cell patients in Phase 3 trial. Pfizer will continue developing its broader sickle cell portfolio. Get the latest proven ETF strategies to target and profit from summer volatility before the next big market swing. Pfizer Inc.
Can Rising Casgevy Sales Aid CRISPR Therapeutics Post Q2 Earnings?
CRSP's Casgevy records a 114% sales jump sequentially in Q2, fueling optimism for sustained revenues and long-term growth.
BEAM's Q2 Loss Narrower Than Expected, Revenues Miss Mark
Beam Therapeutics posts narrower second-quarter loss but misses revenue estimates. The company provides updates on pipeline progress.
Beam Therapeutics Inc. ( BEAM ) Reports Q2 Loss, Misses Revenue Estimates
Beam Therapeutics (BEAM) delivered earnings and revenue surprises of +3.85% and -38.59%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results
WALTHAM, Mass., July 31, 2025 ( GLOBE NEWSWIRE ) -- Apellis Pharmaceuticals, Inc. ( Nasdaq: APLS ) , today announced its second quarter 2025 financial results and business highlights.
Vir Biotechnology, Inc. ( VIR ) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Vir Biotechnology (VIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
CRISPR-based innovators like NTLA, EDIT and PRME are gaining traction as genomics reshapes the future of medicine and biotech ...
